肿瘤细胞治疗研究
英文原题：Diffuse intrinsic pontine glioma in the era of H3 K27-altered diffuse midline glioma.
弥漫性内生性桥脑胶质瘤（DIPG），在病理上最常对应为弥漫性中线胶质瘤（DMG），H3 K27变异型，仍然是一种极为致命的儿童脑干恶性肿瘤，中位总生存期约为11个月。
弥漫性内生性桥脑胶质瘤（DIPG），在病理上最常对应为弥漫性中线胶质瘤（DMG），H3 K27改变型，仍然是一种极为致命的儿童脑干恶性肿瘤，中位总生存期约为11个月。我们通过结构化检索（截至2025年12月31日）严格综合了所识别的证据，并补充了截至2026年7月对监管文件、临床试验记录以及关键性或实践相关出版物的针对性更新。我们总结了流行病学和临床-影像学综合征；审视了在立体定向活检支持下向整合分子分类的转变，其中液体活检正逐渐成为一种补充工具；并提炼了以PRC2抑制、H3K27三甲基化缺失、发育细胞状态、神经元-胶质瘤相互作用以及涉及TP53/PPM1D、ACVR1、PDGFRA和PI3K/MAPK通路的复发性共改变为核心的基础生物学。放疗仍然是唯一具有可重复但短暂临床获益的治疗方式；证据支持在选定患者中采用大分割放疗，并对复发时经过仔细筛选的患者进行再照射。我们评估了为什么细胞毒性化疗以及大多数靶向或表观遗传学方法未能带来可重复的获益，同时强调了CAR T细胞疗法、新抗原疫苗接种、溶瘤病毒疗法以及局部或超声介导递送所显示的早期信号。我们还审视了dordaviprone，这是首个获得FDA加速批准用于既往治疗后疾病进展的H3 K27M突变型DMG的全身性疗法，同时强调监管有效性人群排除了DIPG，因此并未确立其在经典儿童桥脑疾病中的疗效。试验设计还必须明确区分解剖表型与分子分类。优先事项包括分子分层入组、经药代动力学验证的脑干暴露、合理的联合方案，以及整合生存、神经功能和生活质量的终点。
Diffuse intrinsic pontine glioma (DIPG), most commonly corresponding pathologically to diffuse midline glioma (DMG), H3 K27-altered, remains an overwhelmingly lethal pediatric brainstem malignancy, with median overall survival of approximately 11 months. We critically synthesized evidence identified through a structured search to December 31, 2025, supplemented by targeted updates of regulatory documents, clinical-trial records, and pivotal or practice-relevant publications through July 2026. We summarize epidemiology and the clinico-radiographic syndrome; examine the transition toward integrated molecular classification supported by stereotactic biopsy, with liquid biopsy emerging as a complementary tool; and distill core biology centered on PRC2 inhibition, loss of H3K27 trimethylation, developmental cell states, neuron-glioma interactions, and recurrent co-alterations involving TP53/PPM1D, ACVR1, PDGFRA, and PI3K/MAPK pathways. Radiotherapy remains the only modality with reproducible, albeit transient, clinical benefit; evidence supports hypofractionation in selected patients and reirradiation for carefully selected patients at recurrence. We appraise why cytotoxic chemotherapy and most targeted or epigenetic approaches have failed to deliver reproducible benefit, while highlighting early signals from CAR T-cell therapy, neoantigen vaccination, oncolytic virotherapy, and locoregional or ultrasound-enabled delivery. We also examine dordaviprone, the first systemic therapy to receive FDA accelerated approval for H3 K27M-mutant DMG with progressive disease following prior therapy, while emphasizing that the regulatory efficacy population excluded DIPG and therefore does not establish efficacy in classic pediatric pontine disease. Trial design must also explicitly separate anatomic phenotype from molecular taxonomy. Priorities include molecularly stratified enrollment, pharmacokinetically verified brainstem exposure, rational combinations, and endpoints integrating survival, neurologic function, and quality of life.
MEMBER ACCOUNT
登录成功会直接打开下一页。
